Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.

In a report released yesterday, William Wood from B. Riley Securities maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $...

Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Madrigal Pharmaceuticals. The company’s shares cl...

Market Cap	$12.70B	P/E Ratio	N/A
52W High	$577.90	52W Low	$265.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-14.4%	52W Position	90.4%
Overall Score	53	Value Score	40
Quality Score	--	Technical Score	66

EPS Current Est	$-9.66	EPS Next Est	$5.38
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$547.96	+1.08%	567.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$547.96	+1.1%	567.23K
3
4
5
6

MDGL

MDGL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Madrigal Pharmaceuticals Inc. Data in Excel

Get Madrigal Pharmaceuticals Inc. Data in Excel